Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".

Authors	Mary Lou Affronti, James E Herndon 2nd, Mallika P Patel
Journal	Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Support Care Cancer) Vol. 28 Issue 12 Pg. 5591-5592 (12 2020) ISSN: 1433-7339 [Electronic] Germany
PMID	32885313 (Publication Type: Letter, Comment)
Chemical References	Antineoplastic Agents Aprepitant Ondansetron Temozolomide
Topics	Antineoplastic Agents (adverse effects) Aprepitant (therapeutic use) Glioma (drug therapy) Humans Nausea (chemically induced, drug therapy, prevention & control) Ondansetron (adverse effects) Temozolomide (adverse effects) Vomiting (chemically induced, drug therapy, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!